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The cancer microenvironment, which incorporates interactions with stromal cells, extracellular matrix
(ECM), and other tumor cells in a 3-dimensional (3D) context, has been implicated in every stage of cancer
development, including growth of the primary tumor, metastatic spread, and response to treatment. Our
understanding of the tumor microenvironment and our ability to develop new therapies would greatly
benefit from tools that allow us to systematically probe microenvironmental cues within a 3D context.
Here, we leveraged recent advances in microfluidic technology to develop a platform for high-throughput
fabrication of tunable cellular microniches (‘‘microtissues’’) that allow us to probe tumor cell response to a
range of microenvironmental cues, including ECM, soluble factors, and stromal cells, all in 3D. We further
combine this tunable microniche platform with rapid, flow-based population level analysis (n . 500),
which permits analysis and sorting of microtissue populations both pre- and post-culture by a range of
parameters, including proliferation and homotypic or heterotypic cell density. We used this platform to
demonstrate differential responses of lung adenocarcinoma cells to a selection of ECM molecules and
soluble factors. The cells exhibited enhanced or reduced proliferation when encapsulated in fibronectin- or
collagen-1-containing microtissues, respectively, and they showed reduced proliferation in the presence of
TGF-b, an effect that we did not observe in monolayer culture. We also measured tumor cell response to a
panel of drug targets and found, in contrast to monolayer culture, specific sensitivity of tumor cells to
TGFbR2 inhibitors, implying that TGF-b has an anti-proliferative affect that is unique to the 3D context and
that this effect is mediated by TGFbR2. These findings highlight the importance of the microenvironmental
context in therapeutic development and that the platform we present here allows the high-throughput
study of tumor response to drugs as well as basic tumor biology in well-defined microenvironmental
niches.
Introduction
The cellular microenvironment, which includes soluble
signals such as growth factors and hormones, as well as
insoluble signals such as cell–cell and cell–matrix interactions,
regulates key aspects of healthy and diseased tissue functions.
This observation is particularly relevant in cancer, where the
microenvironment has been shown to play a critical role in
tumor development, metastasis, and drug resistance.1–4 For
example, drug resistance in tumor cells can be modulated by
the addition of stromal cells5 as well as culture in 3D
spheroids6–9 or encapsulation in a synthetic or natural
extracellular matrix (ECM).10,11 The unique phenotypes
demonstrated in 3D cell culture are due to changes in a
variety of microenvironmental factors, including altered cell–
cell contacts, diffusion of nutrients and signaling mediators,12
and integrin ligation with growth factor pathway crosstalk.12–15
Because cellular behavior is dependent on architectural cues,
studying microenvironmental influences on cancer progres-
sion in 3D could offer unique opportunities. Animal models
inherently include critical microenvironmental cues and three-
dimensional tissues, but they lack the throughput required for
many applications. In vitro tumor models that allow us to
control microenvironmental cues specifically in a 3D context
may provide a complementary tool to bridge 2D and in vivo
studies, and may more accurately predict in vivo cancer
progression and response to therapeutics.
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Systematic exploration of microenvironmental cues for
many applications, such as drug screening, requires high-
throughput platforms that incorporate rapid production and
analysis of combinatorial 3D tissue constructs. Microscale
versions (100–500 mm) of cell-laden gels (‘‘microtissues’’) can
incorporate a range of co-encapsulated stromal and external
diffusible cues. Microtissues have been fabricated by various
methods including photolithography,16,17 micromolding,18
and emulsification,19 but the majority of these techniques
are limited in throughput or result in extremely polydisperse
microtissue populations. A promising method for high-speed
production of microtissues is droplet-based cell encapsulation,
wherein a cell–prepolymer mixture is emulsified on-chip by a
shearing oil stream and polymerized while in droplets.20 This
process has been demonstrated for a variety of ECM materials,
including polyethylene glycol (PEG),20 alginate,21,22 collagen,23
and agarose,24 is compatible with a range of cell types (.90%
encapsulation efficiency), and rapidly produces large numbers
of monodisperse microtissues (6000 gels min21). Although
droplet devices facilitate high throughput microtissue fabrica-
tion, to date analysis of droplet-derived microtissues has relied
on serial imaging. While imaging is information-rich, it is
labor-intensive and would become a bottleneck in the context
of high-throughput screening, especially with large numbers
of microtissues. One solution for increasing analytical
throughput is the use of an in-flow sorting and analysis
system, similar to flow cytometry, that can analyze and sort
microtissues on multiple parameters, such as cell density, size
and composition based on time-of-flight, extinction, absor-
bance, and fluorescence. The capability of such a system to
quantify fluorescent reporter expression has been demon-
strated using microtissues that represent stages of liver
development and disease (n ¢ 102–103, fabricated by
photolithography).25 Combining high-speed in-flow analysis
with a high-throughput microtissue fabrication would produce
an ideal system for combinatorial microenvironmental mod-
ulation that could be used in high-throughput biology and
screening cancer therapeutics.
In this report, we combine microfluidic cell encapsulation
with large-particle flow analysis to present an integrated
platform for studying the effects of microenvironmental cues
(cellular, ECM, growth factors, drugs) on tumor cell prolifera-
tion in various 3D contexts. To specifically interrogate the
impact of various microenvironmental inputs, tumor and
stromal cells were incorporated into droplets at high densities
and cell–ECM interactions were controlled by physically
entrapping full-length matrix proteins within the encapsulat-
ing hydrogel. Furthermore, we leveraged the native stochasti-
city generated during microfluidic encapsulation to generate
diverse subpopulations of microtissues that contain varied
degrees of homotypic and heterotypic interactions, and we
isolated those subpopulations using flow sorting to generate
highly defined microenvironments. As the primary readout,
sorted populations cultured with and without exposure to a
panel of soluble factors were re-examined via flow analysis to
rapidly record large-scale population data (n . 500 events).
Finally, we applied this platform to investigate the influence of
TGF-b signaling, which is known to be strongly context-
dependent and can be either tumor suppressing or cancer
promoting, on tumor cell proliferation. We report the outcome
of a proof-of-principle drug candidate screen on KrasLSL2G12D/+;
p53flox/flox mouse non-small-cell lung cancer (NSCLC) derived
cell lines.26 This screen revealed differing sensitivities of these
particular lines to TGF-b signaling in 3D that were not
observed in 2D. Our ability to study tumor biology and to
develop effective new therapies will require systematic study of
tumor cells within a microenvironmental context. The plat-
form that we have developed provides a high-throughput
method to study drug response and tumor biology within
highly-defined microenvironmental niches.
Materials and methods
Tunable microtissue synthesis
Microfluidic device fabrication and cell encapsulation have
been described previously.20 Briefly, cells or a mixture of cells
were injected into the device as an isopycnic suspension and
mixed on-chip with 26 concentrated photopolymerizable
polyethylene glycol prepolymer. For microtissues functiona-
lized with matrix proteins, collagen I (rat tail, BD Biosciences),
fibronectin (human, Millipore), or laminin (murine, Sigma)
were included in the concentrated prepolymer at 40 mg ml21.
The combined aqueous stream, consisting of 10% (w/v) PEG-
DA (20 kDa, Laysan), 0.1% (w/v) Irgacure-2959 (Ciba), 1% (v/v)
N-vinyl pyrrolidone (Sigma-Aldrich), up to 20 mg ml21 ECM
proteins, and up to 50 6 106 cells ml21, was sheared into
droplets by fluorocarbon oil at a flow-focusing junction.
Downstream, ultraviolet light (Exfo Omnicure, 500 mJ cm22)
was used to crosslink droplets into spherical cell-laden
hydrogels. Microtissue size was controlled by adjusting the
oil/prepolymer flow rates (typically 800 ml h21 and 200 ml h21,
respectively) to produce monodisperse microtissues between
50–120 mm that were collected and washed in media before
preliminary analysis and sorting.
Large-particle flow cytometry
Microtissue reporter and cell fluorescence levels were quanti-
fied using a complex object parametric analyzer for handling
500 mm objects (COPAS Select, Union Biometrica) according to
the manufacturer’s instructions. Samples were first gated by
time-of-flight (size) vs. extinction (optical density) to exclude
cell debris and aggregates. Gated microtissues were then
analyzed for Green (gain: 300) and FarRed (gain: 850, 250%
Green compensation) fluorescence and sorted into multiwell
plates filled with media. Post-sorting, microtissues were
washed in PBS by filtering through 40 mm nylon strainers,
resuspended in media, and transferred to low-attachment
plates for culture and treatment. COPAS data was re-gated and
processed using custom MATLAB code.
Cell culture
Murine cell lines 393T5 and 394T4 have been previously
described.26 Briefly, tumors were initiated in KrasLSL2G12D/+;
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p53flox/flox mice with intratracheal lentiviral-Cre vectors.
Tumors were then excised from the mice, enzymatically
digested, and subsequently plated onto tissue culture treated
plastic to generate cell lines. Cell lines were transfected with
ZsGreen33 and subsequently cultured in Dulbecco’s Modified
Eagle Medium (DMEM, Invitrogen) with 10% fetal bovine
serum (Invitrogen), 10 U ml21 penicillin (Invitrogen), and 10
mg ml21 streptomycin (Invitrogen). J2-3T3 fibroblasts were
cultured in DMEM with 10% bovine serum (Invitrogen), 10 U
ml21penicillin, and 10 mg ml21 streptomycin. All cells were
cultured in a 5% CO2 humidified incubator at 37 uC. To label
fibroblasts prior to encapsulation, cells were detached with
0.25% trypsin-EDTA (Invitrogen) and resuspended in PBS.
CellTracker Far Red DDAO-SE (Invitrogen, 1.18 mM in DMSO)
was added to the cell suspension (1 : 625 dilution) and
incubated for 45 min at 37 uC. The cell pellet was then
centrifuged, washed, and either re-plated (the dye was stable
for several days) or used immediately.
Growth factors and inhibitors
Microtissues were cultured in 10% serum media and treated
with growth factors EGF, TGF-b, VEGF, or HGF (R&D Systems)
at 50 ng ml21. Small molecule inhibitors were dosed into the
microtissue media to a final 10 mM in 0.2% DMSO: SB525334
(Tocris), SJN2511 (Tocris), LY2157299 (Selleckchem), dorso-
morphin dihydrochloride (Tocris), DMH-1 (Tocris), or GW5074
(Tocris).
Tumor cell proliferation in 2D
393T5 cells were detached with 0.25% trypsin-EDTA
(Invitrogen) and replated at a density of 4000 cells/well into
96-well plates. One day post-seeding and daily thereafter, fresh
media and drugs were added and ZsGreen fluorescence was
measured using a microplate reader (Molecular Devices).
Microtissue staining and visualization
Live microtissues were imaged directly for ZsGreen-labeled
tumor cell line fluorescence or CellTracker Far Red-labeled
fibroblasts. Alternatively, microtissues were fixed and permea-
bilized in order to count embedded cell nuclei. To bypass any
difficulties preserving ZsGreen protein fluorescence after
fixation, microtissues containing ZsGreen-labeled cells were
additionally incubated with CellTracker Green CMFDA
(Invitrogen) prior to being fixed (4% paraformaldehyde).
Microtissues were then permeabilized (0.05% Triton X-100),
and stained with Hoechst 33342 (Invitrogen). Images were
acquired with a Nikon Ellipse TE200 inverted fluorescence
microscope, a CoolSnap-HQ Digital CCD Camera, and
MetaMorph Image Analysis Software. NIH software ImageJ
was used to uniformly adjust brightness/contrast, pseudoco-
lor, and merge images.
Statistical analysis
Data are presented as mean¡ SEM, except for microtissue cell
counts which are described as mean ¡ standard deviation.
Samples were compared using one-way ANOVA, with p-values
of ,0.05 considered statistically significant.
Results and discussion
Platform design
Many techniques for 3D tumor culture have been developed,
including encapsulating cells within bulk hydrogels of specific
scaffold materials, to control stiffness and ECM composition.
However, these systems do not miniaturize readily for high-
throughput studies, especially in situations when cells or
reagents are limiting. Further, readouts for larger gels often
require imaging,15 which is slow and laborious, or biochemical
assays that provide only a global measurement averaged over
many local microenvironments. Alternatively, formation of 3D
tumor spheroids7 has been useful in elucidating the impor-
tance of architecture on tumor phenotype. Unfortunately,
these niches do not incorporate the kind of microenviron-
mental control that is available through tuning the physical
and biochemical properties of engineered scaffolds.27
To generate homogeneous populations of defined micro-
tissues for evaluating proliferative potential under designated
microenvironmental and soluble cues, we established an
experimental workflow that can be divided into five phases
(Fig. 1). First, fluorescently labeled tumor cells are micro-
fluidically encapsulated with the desired combination of
stromal cells or ECM into synthetic 3D microtissues
(Fig. 1A). We chose poly(ethylene glycol) diacrylate (PEG-DA,
20 kDa) as the hydrogel material because it provides a
biocompatible, non-stimulatory background, and unlike other
scaffold materials, such as collagen or agarose, PEG can be
chemically decorated with integrin binding peptides,28 pro-
teins,29 and other ligands.30
In the second phase, a large-particle flow analyzer is used to
initially characterize freshly generated microtissues in multi-
ple channels of embedded-cell fluorescence (Fig. 1B). Defined
populations of microtissues are selected and sorted by tumor
and/or stromal cell density (Fig. 1C). These steps are required
because microfluidic cell encapsulation is an inherently
stochastic process: for small numbers of cells, a wide range
of cell numbers will be encapsulated in each microtissue. In
the best-case scenario, theory suggests that the distribution of
cells within microtissues will be determined by Poisson
statistics.20 However, due to issues of cell settling and
aggregation at high cell densities, the cell distribution will
often be much more variable in practice. Systems have been
optimized to encapsulate single cells,31,32 but controllably
encapsulating 10–100 cells, which are closer to the cell density
used in spheroid culture,9 is more challenging. While working
in this cell density regime, unavoidable variations in micro-
tissue density and composition of different cell types can
reduce the statistical power of the analysis. For example, if a
microtissue population (n = 500) immediately post-encapsula-
tion has a standard deviation that is 36 the mean
fluorescence (s/m = 3), one could measure a 40% difference
in proliferation with 80% statistical power. Since the popula-
tion spread usually increases over the course of the experiment
due to biological variation, this power would decrease even
further for later time points. By contrast, using a pre-sort,
initial spreads are constrained to approximately s/m = 0.2, with
final standard deviations between s/m = 0.5 to 1. With these
This journal is  The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 1969–1978 | 1971
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sorted populations, even changes as small as 13% could be
detected with 80% statistical power. Further, we take
advantage of the initial heterogeneity of the population to
produce multiple ‘‘bins’’ of encapsulated cell numbers from a
single encapsulation step.
In the next phase, sorted microtissues are collected in
tissue-culture wells for culture over 2–6 days, during which
time they can be treated with soluble growth factors or drugs
(Fig. 1D). During this time, cells proliferate within the
microtissues and can be visualized by microscopy. At the
desired time point, treated microtissues are collected and re-
analyzed by large particle cytometry for changes in overall
fluorescence of the embedded cells (Fig. 1B). This method
offers higher throughput than methods that require serial
imaging as a readout, and unlike traditional bioassays that
require release of cells from the microgels, our whole-
microtissue flow measurement is non-destructive. After every
analysis step using our platform, each microtissue population
can be re-collected for additional culture periods and
subsequent analysis, allowing us to study the evolution of a
single population over time.
Controlling tumor homotypic and heterotypic interactions
Cell–cell interactions, both homotypic and heterotypic, are
among the most potent modulators of cellular function. Our
platform was designed to generate uniform populations of
microtissues of user-defined tumor cell (homotypic) and/or
accompanying stromal cell (heterotypic) densities. To demon-
strate control over homotypic density, we generated a parent
population of microtissues, incorporating a range of numbers
of murine non-small cell lung cancer cells (393T5) bearing a
constitutive fluorescent reporter protein (ZsGreen). The 393T5
NSCLC cell line was established from a primary tumor that
formed distant metastases.26 Because total microtissue fluor-
escence, as measured using the COPAS, exhibits a linear
correlation with cell number (Fig. S1, ESI3), we divided our
parent population into multiple subpopulations by enriching
each bin for a particular range of encapsulated cells (Fig. 2A).
Examination of subpopulations immediately post-sorting
reveals three distinctly separated, narrow peaks (Fig. 2A).
After three days in culture, cell growth within microtissues
yields populations that remained separable, demonstrating
the ability to control homotypic density over time (Fig. 2A).
During these several days in 3D culture, tumor cells that were
originally encapsulated as single cells (Fig. 2B) gave rise to
tumor spheroids within the microtissues (Fig. 2C), whereas the
same cells typically grow as a monolayer when placed in 2D
culture.33 Compared to spheroid models, which require
several days to form 3D aggregates, multicellular microtissues
in our platform are formed with no time delay. Furthermore,
the size and cellular density of spheroids may vary over time
due to proliferation and/or contractile forces. The microtissues
Fig. 1 3D tumor microenvironment screening platform. (A) Microfluidic droplet-
based encapsulation of tumor cells into microtissues that can be tuned with co-
encapsulated stromal cells or entrapped ECM molecules. (B) The microtissues
produced are rapidly interrogated in multiple fluorescent channels using large-
particle flow analysis. (C) Cytometry-like flow sorting separates and defines
microtissues with controlled levels of homotypic and heterotypic interactions.
(D) Cellular microenvironment within microtissues is further modulated by
soluble factors such as cytokines or small molecule drugs. The extent of cell
proliferation within individual microtissues is then detected by flow analysis (B)
to collect population-level data on responses to microenvironmental conditions.
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formed in this study display 3D growth features and allow
control of volumetric cell density and interstitial scaffold
material.
In addition to the influence of homotypic interactions,
stromal cells exert a significant effect on tumor growth and the
potential for metastasis.1,4,34 In order to study the impact of
these cellular interactions, previous studies have varied the
stromal cell to parenchymal cell composition within micro-
gels, albeit at lower cell densities, by changing the flow rates of
two corresponding cell streams.24 This ‘‘pre-encapsulation’’
control strategy yields the desired stromal:parenchymal cell
compositions, at least on average, but the specific ratio in a
given microgel varies widely across the population. For
example, if two cell types are mixed at a density to give on
average 8 cells per gel at a 1 : 1 ratio, Poisson statistics dictate
that only 14% of the resulting gels will actually have equal
numbers of the two cells. For an average 1 : 3 stromal to
parenchymal ratio, even fewer gels will contain 1 : 3 cell
numbers, with many gels containing no stromal cells at all.24
To exert finer stoichiometric control of tumor and stroma
‘‘post-encapsulation’’, we incorporated stromal cells into our
microtissue models by mixing and co-encapsulating the 393T5
cells with J2-3T3 murine fibroblasts, and generated a parent
population of microtissues from one prepolymer mixture with
a range of tumor to stroma ratios. Subsequently, we performed
a 2-parameter sort with green and far red fluorescence
representing the number of cancer cells and co-encapsulated
fibroblasts, respectively (Fig. 2D). We were able to separate the
parent population into low (2.5 ¡ 0.3 cells per gel) and high
(5.0 ¡ 1.7 cells per gel) numbers of fibroblasts, while holding
the number of the cancer cells constant (7.0 ¡ 2.7 cells per
gel), thus generating distinct populations with a two-fold range
of stromal to cancer ratios, but consistent cancer cell density
(Fig. 2E). By defining stromal composition ‘‘post-encapsula-
tion’’ rather than ‘‘pre-encapsulation,’’ we take advantage of
the stochasticity of encapsulation to generate multiple
populations with different ratios from a single microfluidic
process. This allows us to establish populations with a wide
Fig. 2 Control over homotypic and heterotypic microtissue composition. (A) Histograms of ZsGreen-labeled 393T5 (lung cancer-derived cell line) microtissue
populations, using sorted ZsGreen fluorescence as a measure of homotypic density, before (Day 0) and after (Day 2) proliferation. (B) Phase and epifluorescence
images of 393T5 cells embedded within microtissues at various cell densities and stained with CellTracker Green CMFDA. (C) Growth of CellTracker CMFDA stained
393T5 cells within microtissues into spheroids over four days. (D) Microtissues containing 393T5 cells co-encapsulated with CellTracker FarRed stained fibroblasts,
sorted by stromal cell density (Red fluorescence) while maintaining desired tumor cell density (ZsGreen fluorescence) to achieve a two-fold change in stromal:tumor
cell ratio between the High vs. Low populations. (E) Phase and epifluorescence images of 393T5 cells (ZsGreen) co-encapsulated with J2-3T3 cells at different ratios. All
scale bars: 50 mm.
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dynamic range of absolute cell numbers as well as cellular
composition patterns. Further, the tunability of the sorting
parameters (Fig. S2, ESI3) allows user-defined tolerances to set
the desired spread of cell ratios, which will in general be
tighter than those achieved using control over average cell
concentrations alone. Therefore, by controlling the bin thresh-
olds, subsequent studies can be performed on populations in
which every individual, sorted microtissue contains stromal
cells at a particular ratio.
Modulating cell proliferation with microenvironmental factors
At the molecular level, ECM and soluble factors play a large
role in modulating cellular function. In cancer, VEGF secretion
stimulates angiogenesis, which is a critical component of
tumor growth.35 Similarly, matrix remodeling is correlated
with a more invasive phenotype.1,36 We were interested in the
ability to test how cytokines and ECM modulate metastatic
potential in a 3D context, using proliferation as a surrogate for
invasive growth. The composition of our PEG-DA hydrogels (10
wt%, 20 kDa) was chosen to form a semi-permeable network (7
nm mesh size37) that allows diffusion of soluble proteins with
sizes up to 100 kDa,38 which includes most cytokines. First, we
encapsulated 393T5 cells in microtissues, and we sorted them
to enrich for a particular homotypic density (17.4 ¡ 3.4 cells
per gel), which we held constant across experiments. Then we
cultured the enriched microtissue population for two days in
media supplemented with growth factors that have been
widely implicated in cancer progression: 50 ng ml21 of EGF,
HGF, VEGF, or TGF-b (Fig. 3A). Exposure to EGF, HGF, and
VEGF had no significant effect on proliferation as compared to
vehicle control-treated microtissues. The lack of impact of EGF
is consistent with the fact that these cells overexpress Kras,
which is downstream of the EGF receptor.26,35 Interestingly,
treatment with TGF-b led to a significant reduction in
proliferation (p , 10210). TGF-b is known to have a tumor
suppressor effect in some early-stage cancers but has also been
shown in other cases to promote metastasis, leading to
epithelial to mesenchymal transition, especially in later stage
cancers.39 While the 393T5 cell line was derived from a
primary tumor with proven metastatic potential, our data
suggest that the primary tumor still displays an early-stage
phenotype that can be suppressed by TGF-b, consistent with
observations of other primary lung cancer models.40
In addition to examining the impact of soluble factors, we
also applied our platform to study the effect of ECM proteins
on metastatic potential in 3D. ECM interactions with cell
integrins are known to not only trigger direct downstream
signaling, but also to modulate the response of cells to other
inputs such as drugs and growth factors through pathway
crosstalk.41,42 To include ECM in our microtissues, we co-
encapsulated 393T5 cells with collagen I (300 kDa), laminin
(850 kDa), or fibronectin (440 kDa), adding 20 mg ml21 of the
protein to the pre-polymer mixture so that it is physically
incorporated within microtissues during photopolymerization.
Due to the size of the hydrogel network, large proteins (.150
kDa) are able to diffuse only very slowly through the gel (Fig.
S3, ESI3). Therefore, we expect that the even larger ECM
proteins remain effectively entrapped in the microtissues over
the timescale of our experiments. Also, at this low concentra-
tion, the ECM proteins are unlikely to significantly impact the
physical properties of the 100 mg ml21 PEG-DA hydrogel.
Thus, baseline nutrient diffusion and cell growth rates are
comparable, allowing a horizontal comparison of ECM
molecule signaling effects in 3D using minimal amounts of
Fig. 3 Modulation of tumor cell proliferation by cytokines and ECM. 393T5
growth within microtissues (initial 17.4¡3.4 cells per gel) when (A) cultured in
media containing 50 mg ml21 VEGF, HGF, EGF, or TGF-b, or (B) encapsulated in
the presence of to 20 mg ml21 of laminin, fibronectin, or collagen-1 that remain
physically entrapped within the hydrogel scaffold. Average number of cells per
gel calculated from microtissue fluorescence using linear regression. * indicates
p , 0.01.
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expensive ECM materials, and without the confounding factor
of varying mechanics (e.g. collagen gels vs. fibrin gels) or
network properties. ECM-functionalized microtissues enriched
for a specific homotypic density were sorted and cultured for 2
days (Fig. 3B). Consistent with their pro-metastatic phenotype,
the tumor-derived cells exhibited significantly elevated pro-
liferation in the presence of fibronectin (p , 10210), which has
been shown previously to correlate with metastatic activity.43,44
In contrast, growth was inhibited in the presence of both
laminin (p , 0.01) and collagen I (p , 1024), again
demonstrating a tumor cell preference for proliferation in an
invasive-supporting matrix over basement membrane pro-
teins. Additionally, collagen I has been reported to induce
TGF-b3 expression in some lung cancer cells,45 which could
lead to an indirect growth inhibition mediated by this ECM,
consistent with our observations in response to TGF-b
exposure, described above (Fig. 3A).
Microenvironmental modulation of tumor drug response
Having demonstrated that our sortable microtissue platform
can be used to assess the responsiveness of tumor cell
populations to soluble as well as embedded matrix proteins,
we sought to apply this system to conduct a small-scale pilot
drug screen. In contrast to conventional 3D gels, miniaturized
tumor microtissues offer an advantage for screening purposes
in that reagent costs can be reduced, especially with respect to
the amount of drug needed to treat a certain media volume,
while the number of replicates is maximized. Combined with
its high-throughput readout that will reduce experimental
time and effort needed per drug, our platform offers extreme
scalability to support even broader screens. As a first proof of
concept, we hypothesized that this platform could be used to
probe candidate drugs that impact tumor cell proliferation
specifically in a 3D architecture, as opposed to any outcomes
observed in conventional 2D culture conditions. Given that
exogenously supplied TGF-b inhibits 393T5 proliferation
(Fig. 3A), and perturbations in TGF-b signaling have been
found to be strongly tumor- and context-dependent,39 we
selected several small-molecule inhibitors that disrupt aspects
of the TGF-b signaling pathway: SB525334 (TGFbR1), SJN 2511
(TGFbR1), and LY2157299 (TGFbR2, TGFbR1). Dorsomorphin
(AMPK, ALK2, ALK3, ALK6), DMH-1 (ALK2), and GW5074 (c-
raf) were also tested and all treatments were compared to the
growth of DMSO vehicle-treated microtissues, or TGF-b as a
negative control for 3D growth. For 3D assays, encapsulated
393T5 cells were sorted for a specific population density and
cultured for several days in the presence of 10 mM of the
inhibitors. Proliferation was assayed based on the change in
microtissue fluorescence over time. We compared these
results to those found in a 2D assay, where 393T5 cells were
seeded on tissue culture microplates and proliferation was
tracked by microplate well fluorescence.5
Using this assay, we detected statistically significant altera-
tions in microtissue proliferation in response to several of the
drug candidates, relative to untreated and DMSO controls
(Fig. 4A). The TGFbR1 inhibitor, SB525334, was one of several
compounds that exerted similar effects in both 3D and 2D
conditions, in that it led to reduced proliferation in each case
(Fig. 4B). Dorsomorphin caused cell death in both geometries,
and GW5074 elicited little to no anti-proliferative effect
(Fig. 4A, B). However, we noted marked differences between
2D and 3D responses to TGF-b and LY2157299. Specifically,
while TGF-b inhibited proliferation in 3D as observed
previously, the cytokine did not exert any significant effect in
2D. The opposite trend was observed in response to the
TGFbR1/TGFbR2 inhibitor, LY2157299, in that it inhibited
proliferation in 2D cultures, but did not alter 3D microtissue
growth (Fig. 4A, B). We extended our observations by repeating
the drug screen using a second cell line isolated from a mouse
with the same genetic background (394T4). Consistent results
were obtained when the growth responses of drug-treated,
sorted microtissues bearing 394T4 cells were compared to 2D
cultures (Fig. 4C, D). LY2157299 is a clinically relevant
compound undergoing trials for use in a variety of cancer
patients,46–48 and has been reported to bind to both receptors,
but to TGFbR2 with greater specificity (IC50 2 nM vs. 86 nM for
TGFbR1).49 Canonically, TGF-b binds to TGFbR2, which then
recruits and phosphorylates TGFbR1. However, it is known
that specific TGF-b receptors regulate different activities
induced by TGF-b, possibly due to the recruitment of
alternative signaling complexes.50 Specifically, several pub-
lished accounts point to TGFbR2 primarily regulating DNA
synthesis, whereas TGFbR1 has been suggested to have a
greater impact in mediating matrix synthesis or degrada-
tion.51–53 This distribution of functions could be one explana-
tion for why only LY2157299 (inhibiting TGFbR2 for DNA
synthesis in addition to TGFbR1) would exhibit the context-
dependent but opposing effects on proliferation compared to
direct TGF-b treatment, whereas the TGFbR1-only inhibitors
(SB525334, SJN2511) did not.
Given the vast, often contradictory, published literature
regarding the roles of TGF-b and its receptors, particularly in
cancer biology, the impact of drugs may be highly contextual
and dependent on tumor models, culture conditions or
architectures. This pattern is particularly well-illustrated in
our current results and also serves to emphasize the value and
importance of evaluating drug candidates in multiple in vitro
model systems–perhaps in parallel with established therapeu-
tics in order to calibrate the specific assay readout. In this
case, the observation that a TGF-b receptor inhibitor exerts
opposing effects on tumor cell proliferation when compared
with responses to its ligand is perhaps not unexpected.
However, the fact that this same pattern is consistently
reversed in our 2D in vitro architecture raises important
caveats with respect to the potential responsiveness of tumor
cells when this pathway is manipulated in vivo in a clinical
setting. Notably, a finding consistent with our result was
observed by another group examining a mouse model of
metastatic breast cancer.54 In their system, activated TGFbR1
delayed primary tumor growth and accelerated formation of
lung metastases, whereas addition of dominant-negative
TGFbR2 had the opposite effect. The authors speculate that
TGF-b functions as a tumor suppressor in a primary lesion, but
promotes metastasis dissemination, which is consistent with
our findings that primary-tumor derived lung cancer cells
remain responsive to TGF-b stimulation.
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Conclusions
We have demonstrated a platform that integrates microfluidic
droplet encapsulation to produce microscale tunable micro-
environments with a high speed analytical system based on in-
flow sorting and analysis of microtissues. This platform
leverages tissue engineering materials and methods as well
as microfluidic technology, but obviates common problems
with 3D tissue engineering constructs, such as laborious
fabrication, low-throughput imaging analysis, and low statis-
tical power. The capacity for high-speed analysis enables the
detection of hundreds to thousands of individual events in
order to assay the impact of microenvironmental conditions
on proliferation. Moreover, by sort-based enrichment of
defined microtissue populations to limit variability in cell
number and/or composition, our platform reduces noise while
increasing replicates, which offers the potential to achieve
strong statistical significance in biological studies. We used
this platform to explore the impact of TGF-b signaling on non-
small cell lung cancer proliferation. We demonstrated micro-
environmentally-mediated modulation of tumor cell prolifera-
tion in this platform and we observed context-dependent
signaling via the TGF-b pathway in our model cell lines.
Modification of the microtissue scaffold with collagen-1, or
treatment of microtissues with TGF-b, diminished cancer cell
proliferation uniquely in the 3D setting. Furthermore, a
Fig. 4 Comparison of 393T5 (A–B) and 394T4 (C–D) lung cancer cell response to drugs when cultured in 3D microtissues (A,C) vs. in 2D monolayers (B,D). Cells were
treated in both formats with 10 mM of SB525334 (TGFbR1), SJN 2511 (TGFbR1), LY2157299 (TGFbR2, TGFbR1), Dorsomorphin (AMPK, ALK2, ALK3, ALK6), DMH-1
(ALK2), or GW5074 (c-raf), or 50 ng ml21 of TGF-b. Microtissue or tissue-culture well fluorescence for each condition are shown after 3 days of culture for 393T5 cells
and 5 days of culture for 394T4 cells, which proliferate slower in control conditions, so that the two cell lines undergo the same number of population doublings
during each assay. Initial conditions are labeled in green (3D: 13.5 ¡ 2.5 cells per gel, 2D: 26 6 103 cells cm22). Gray rectangles indicate the range of p = 0.05
significance by ANOVA with Tukey post-hoc test compared to DMSO controls. Red conditions had significantly reduced cell numbers compared to DMSO controls,
whereas blue conditions had significantly increased proliferation rates.
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TGFbR1/TGFbR2 inhibitor (LY2157299), but not TGFbR1-only
inhibitors, decreased proliferation in 2D yet promoted growth
in a 3D context. Based on these results, we predict that the
anti-proliferative influence of TGF-b observed in 3D may be
mediated by TGFbR2. An interesting extension of these
findings would be to conduct a related in vivo preclinical
experiment by treating the tumor-prone genetic mouse
model,26 which gave rise to our 393T5 and 394T4 lines, with
oral LY2157299. Based on our findings, one might predict that
the drug might limit or at least delay the appearance of distant
metastases, but may not impact the development of primary
lung tumors. Future work involving the combined flow-
enrichment of subpopulations of microtissues will apply our
platform to explore combinations of microenvironmental
conditions, such as drug responsiveness in the presence of
particular ECM combinations or ratios of heterotypic stromal
cell contacts. To support an expanded screen of cues, a
microfluidic combinatorial mixer could be incorporated
upstream of droplet encapsulation so that ECM and stromal
composition could be controlled on-chip. Also, new encapsu-
lation devices including multiple parallel droplet nozzles
could augment the microtissue fabrication rate for a full-scale
drug screen. Further utility of this platform may be found in
extension to other tissues and disease contexts including stem
cell or other developmental biology settings, in which the
influence of microenvironmental signals has been challenging
to study in a methodical, manipulable and screen-compatible
fashion.
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